adplus-dvertising
Connect with us

Media

Ideon Media Acquires Cue Digital Media Creating one of the Largest Independent Digital Media Companies in Canada – Yahoo Finance

Published

 on


TipRanks

3 Stocks Trading at Rock-Bottom Prices; Analysts Say ‘Buy’

A new year, a new addition to the stock portfolio – what can make more sense than that? The right time to buy, of course, is when stocks are priced at the bottom. Buying low and selling high may be a bit hackneyed, but it’s true, and truth has staying power.But the markets are up. The NASDAQ rose 43% in 2020, and the S&P 500 showed a gain of 16%. With a market environment like that, finding stocks that are caught in the doldrums is harder than it looks. That’s where the Wall Street pros can lend a hand.We used TipRanks’ database to pinpoint three stocks that fit a profile: a share price that has dropped over 30% in the last 12 months, but with at least double-digit upside potential, according to analysts. Not to mention each has earned a Moderate or Strong Buy consensus rating.Esperion (ESPR)We will start with Esperion, a company that specializes in therapies for the treatment of elevated low-density lipoprotein cholesterol levels – a major factor contributing to heart disease. The company’s main product, bempedoic acid, is now available in tablet form under the brand names Nexletol and Nexlizet.In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14,000 patients with top-line data expected in the second half of 2022. The study covers 1,400 locations in 32 countries around the world.Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. Along with the drop in share value, the company showed a fall in revenue from Q2 to Q3, with the top line collapsing from $212 million to $3.8 million. Since the Q3 report, Esperion announced pricing on a $250 million offer of senior subordinated notes, at 4%, due in 2025. The offering gives the company a boost in available capital for further work on its development pipeline and its marketing efforts for bempedoic acid.Chad Messer, covering ESPR for Needham, sees the note offering as a net positive for Esperion. “We believe this cash position will be sufficient to support Esperion through 2021 and to profitability in 2022… We believe this financing should help put to rest concerns regarding Esperion’s balance sheet. Despite a challenging launch for NEXLETOL and NEXLIZET, product growth has continued in 3Q against the backdrop of a contracting LDL-C market. This growth trajectory suggests potential for a rapid acceleration when conditions improve,” Messer wrote.To this end, Messer rates ESPR shares a Strong Buy, and his price target, at $158, suggests the stock has room for huge growth this year – up to 481% from current levels. (To watch Messer’s track record, click here)Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target of $63.33, implying a one-year upside of 133%. (See ESPR stock analysis on TipRanks)Intercept Pharma (ICPT)Liver disease is a serious health threat, and Intercept Pharma is focused on developing treatments for some of the more dangerous chronic liver conditions, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Intercept has a research pipeline based on FXR, a regulator of bile acid pathways in the hepatic system.FXR’s action affects not just the bile acid metabolism, but also the glucose and lipid metabolisms, and inflammation and fibrosis around the liver. The lead compound, obeticholic acid (OCA), is an analog of the bile acid CDCA, and as such can take a role in the FXR pathways and receptors implicated in chronic liver disease. Treating liver disease through the FXR biology has direct applications for PBC, and is showing promise treating complications from NASH.ICPT shares dropped sharply last summer, when the FDA rejected the company’s application to approve OCA for treatment of NASH-related liver fibrosis. This delays the drug’s potential entry to a lucrative market; there is no current treatment for NASH, and the first drug to win approval will have the lead in reaching a market estimated at $2 billion to $5 billion in potential annual sales. The effect on the stock is still felt, and ICPT remains at its 52-week low point.In reaction, in December of 2020, Intercept announced major changes in top-level management, as CEO and President Mark Pruzanski announced he’s stepping down effective January 1 of this year. He is succeeded by Jerome Durso, formerly the company’s COO, who will also take a post on the Board of Directors. Pruzanski will remain as an advisor, and will hold a director’s position on the company’s Board.Piper Sandler analyst Yasmeen Rahimi takes a deep dive into Intercept’s continuing efforts to expand applications of OCA and to resubmits its New Drug Application to the FDA. She sees the leadership transition as part of these efforts, and writes, “[We] believe that Dr. Pruzanski’s dedication to transform the liver space is still strong, and that he will continue to guide ICPT’s progress as an advisor and Board member. Additionally, we have had the pleasure of working closely with Jerry Durso and believe that he will transform the company and lead ICPT’s success in growing the PBC market and the path to potential approval and commercial launch of OCA in NASH.”Rahimi takes a long-term bullish stance on ICPT, giving the stock an Overweight (i.e. Buy) rating and an $82 price target. This figure indicates an impressive 220% upside for the next 12 months. (To watch Rahimi’s track record, click here)Wall Street is somewhat more divided on the drug maker. ICPT’s Moderate Buy consensus rating is based on 17 reviews, including 8 Buys and 9 Holds. Shares are priced at $25.82, and the average price target of $59.19 suggests an upside potential of 132% for the next 12 months. (See ICPT stock analysis on TipRanks)Gilead Sciences (GILD)Gilead has had a year like a firework – fast up and fast down. The gains came in 1H20, when it appeared that the company’s antiviral drug remdesivir would become a prime treatment for COVID-19. By November, however, even though remdesivir had been approved, the World Health Organization (WHO) was recommending against its use, and the COVID vaccines now on the market have made remdesivir irrelevant to the pandemic.This was only one of Gilead’s recent headwinds. The company has been working, in conjunction with Galapagos (GLPG), on development of filgotinib as a treatment for rheumatoid arthritis. While the drug received EU and Japanese approval in September 2020, the FDA has withheld approval and Gilead announced in December that it was suspending US development efforts on the drug.Even so, Gilead retains a diverse and active research pipeline, with over 70 research candidates at varying stages of the development and approval process for a wide range of diseases and conditions, including HIV/AIDS, inflammatory & respiratory diseases, cardiovascular disease, and hematology/oncology.On a positive note, Gilead posted Q3 earnings above estimates, with the top line revenue, of $6.58 billion, beating the forecast by 6% and growing 17% year-over-year. The company updated its full-year 2020 guidance on product sales from $23 billion to $23.5 billion.Among the bulls is Oppenheimer analyst Hartaj Singh, who gives GILD shares an Outperform (i.e. Buy) rating and $100 price target. Investors stand to pocket a 69% gain should the analyst’s thesis play out. (To watch Singh’s track record, click here)Backing his stance, Singh writes, “We continue to believe in our thesis of (1) a dependable remdesivir/other medicines business against SARS-CoV flares, (2) a base business (HIV/oncology/HCV) growing low-single digits over the next couple of years, (3) operating leverage providing greater earnings growth, and (4) a 3-4% dividend yield.” What does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 10 Buys, 12 Holds and 1 Sell add up to a Moderate Buy consensus. In addition, the $73.94 average price target indicates 25% upside potential from current levels. (See GILD stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Let’s block ads! (Why?)

300x250x1

728x90x4

Source link

Continue Reading

Media

Forget Trump — the American media is on trial in New York – The Hill

Published

 on



300x250x1

Forget Trump — the American media is on trial in New York | The Hill








The views expressed by contributors are their own and not the view of The Hill

It was July 2018, and Michael Avenatti was considering a presidential run. Anyone can consider running for president, I suppose. It’s just that when the lawyer for Stormy Daniels and cable news mainstay did it, important people — theoretically important, at least — in the press took it seriously.

CNN’s Jim Scuitto had Avenatti on to talk about it, and make a bit of a campaign pitch for himself, on July 4. The next day, CNN’s editor-at-large Chris Cillizza, one of the more prominent writers for the website back then, published a piece of analysis with the headline “President Michael Avenatti? Never say never!”

And sure, why not. Avenatti was riding high at the time. A couple months earlier, he was being pitched, according to the New York Times, for a “Crossfire”-like show with Anthony Scaramucci, the rapidly-defenestrated former Trump communications director, by mega-agent Jay Sures, who represents top CNN talent like Jake Tapper and Anderson Cooper. Maybe that’s why Avenatti became so ubiquitous on the network to begin with — embarrassingly so, in retrospect.

But if we look back to April, almost exactly six years ago, that’s when Avenatti truly burst onto the national scene. On April 9, 2018, the FBI raided the office of Michael Cohen, the long-time “fixer” and business associate of then-President Donald Trump. The next day, Avenatti was on Cooper’s CNN show to break it all down — from Stormy Daniels, his porn actress client, to Karen McDougal, the former Playboy playmate, to Cohen himself. It was Avenatti’s chance to craft the narrative for the media, and the media was happy to oblige.

The whole ordeal was portrayed a couple weeks later in a cringe-inducing “Saturday Night Live” cold open, with Ben Stiller playing Cohen, Jimmy Fallon playing Jared Kushner, and Stormy Daniels playing herself. (She struggled to nail the “Live from New York, it’s Saturday Night!” line at the end.)

It’s worth reflecting this week on this bizarre 2018 moment, as it serves as the prelude to the first (and possibly only) trial of Trump in 2024. The trial that officially began on Monday isn’t about “insurrection” or “espionage” or classified documents or RICO. Oh no. It’s this reality TV, trashy tabloid junk about porn stars and Playmates — stuff that belongs more in the National Enquirer than the National Broadcasting Company.

Which is ironic, of course, because the first witness in the case was David Pecker, the former executive in charge of the National Enquirer. (It’s also ironic that Avenatti is now firmly on Team Trump, saying he’d be happy to testify for the defense, although of course he’s also currently in federal prison for wire fraud and tax fraud, so…)

It’s been more than six years since that initial FBI raid, and the original Avenatti media sin. But buckle up, here we go. We’re getting to hear about the way Trump teamed up with the National Enquirer in an effort to boost his 2016 campaign. A bit like how most of the establishment press today is teaming up with the Biden campaign to stop Trump in this cycle.

You know that story about Ted Cruz’s father potentially being involved in the murder of JFK? Totally made up, to help Trump in the primary! None of this is surprising, to any discerning news consumer. But it does allow the media to get on their proverbial high horse over “checkbook journalism” — as if the crusty old legacy press hasn’t been doing a version of it for decades, when ABC or NBC wants to secure a big “get” on their morning show. But the journalistic ethics of the National Enquirer are a red herring — a distraction from the substance of the trial.

After Pecker, we’ll get Cohen, and Daniels, and McDougal as witnesses. Avenatti, at least it seems for now, will stay in prison, and not get to return to the limelight.

This trial is a circus. But the media made their choice way back in 2018. And now they too are on trial.

To get meta for a minute, when I decide to devote my weekly column to a topic, I’m not only deciding the topic to cover, but making a decision about what not to cover as well. On a far larger and more consequential scale, every single news organization makes choices every day about what to focus on, how to cover it and what gets left on the cutting room floor.

Back during the Trump years, the media spent an inordinate amount of time dissecting every last detail of this tabloid journalism fodder we’re now seeing play out in a New York City courtroom — which is meaningless to the lives of nearly every American. The trial is the culmination of the inconsequential work that ate up so many hours of cable news, and occupied so much space in the most powerful media outlets in America. So much time and energy and resources that could have been devoted to literally any other story, including many that directly relate to Donald Trump. And yet now, here we are.

This trial has to matter for the American press. If it doesn’t, it invalidates their entire existence during 2018. But if the public tunes out — and, can you even imagine if a jury in New York City actually finds Trump not guilty at the end of this thing — well, it’s as much an indictment of the Trump-obsessed Acela media as it is of the system that brought these bizarre charges and salacious case in the first place.

Steve Krakauer, a NewsNation contributor, is the author of “Uncovered: How the Media Got Cozy with Power, Abandoned Its Principles, and Lost the People” and editor and host of the Fourth Watch newsletter and podcast.

Tags

Anthony Scaramucci


Chris Cillizza


CNN


David Pecker


David Pecker


Donald Trump


Jay Sures


media


Michael Avenatti


Michael Avenatti


National Enquirer


Stormy Daniels


Stormy Daniels


Copyright 2024 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Media

'Nessie' photo at Scotland's Loch Ness puts Canadians in media spotlight – National Post

Published

 on


The Official Loch Ness Monster Sightings Register sent the photo to one of their experts ‘who said that it was “compelling evidence” ‘ of the creature

Article content

LONDON — Parry Malm and Shannon Wiseman weren’t expecting a “pivotal moment” in their sons’ lives when they visited Scotland’s Loch Ness earlier this month, but that’s exactly what happened.

“Our youngest is turning three next week,” said Wiseman from the family’s home in London, England. “And he tells everyone there have been two pivotal moments in his life: Seeing the world’s largest dinosaur, which he did at the Natural History Museum in January, and seeing Nessie.

Advertisement 2

Article content

Article content

“He tells everyone he encounters. He tells the postman, he tells the guys in the shops and the cafes.”

Malm and Wiseman have been thrust into the limelight after a photo they took during their family vacation showed a shadowy figure poking above the waterline, something that the couple’s children _ and others — firmly believe is the latest sighting of the famed Loch Ness monster.

Malm and Wiseman, who are from Coquitlam B.C., and Calgary respectively, moved to England in 2006.

The couple said the original plan for the spring vacation was to take a boat ride in Loch Ness because their children were “completely captivated by the concept of Nessie.”

“We’d even packed shortbread cookies, which we were told from these books was Nessie’s favourite treat,” Wiseman quipped. “Turned out shortbread cookies were not necessary.”

That’s because the family spotted something sticking out of the water while visiting a lookout at nearby Urquhart Castle.

“We just started watching it more and more, and we could see its head craning above water,” Malm said. “And then it was swimming against the current towards the castle, slowly but surely, like very fastidiously going over the waves (and) coming closer and closer. And then it submerged and disappeared.”

Article content

Advertisement 3

Article content

Recommended from Editorial

  1. FILE - This undated file photo shows a shadowy shape that some people say is a the Loch Ness monster in Scotland, later debunked as a hoax. The Loch Ness Centre in Scotland is calling for

    New search for Loch Ness monster largest since 1972

  2. In a blow to Nessie hunters, they found no evidence of reptilian DNA, ruling out past theories of a Jurassic-era plesiosaur.

    Could the Loch Ness Monster just be a really giant eel?

Malm said the family took a photo of what they saw and decided “for a bit of a laugh” to send the picture to the Official Loch Ness Monster Sightings Register, which he stumbled upon while surfing the internet.

“They got in touch within 24 hours,” Malm recalled. “They were super excited. They sent it to one of their Loch Ness experts who said that it was ‘compelling evidence,’ I believe was the exact phrase.

“And just one thing led to another. I mean, it’s been incredible.”

Since the photo submission, Malm and Wiseman have been featured in British tabloids such as The Sun and the Daily Mirror and digital publication LADbible.

On the Official Loch Ness Monster Sightings Register, the encounter has been recorded as the first Nessie sighting of 2024.

“We’ve both got texts from people who we haven’t heard from in quite some time going, ‘Guess who I just saw on TV?”‘ Malm said.

“I’m just glad that we hit the national media in Canada for spotting the Loch Ness monster and not being on Crime Stoppers.”

Advertisement 4

Article content

Both Malm and Wiseman said they are happy their experience is bringing some positivity to the daily news cycle, and at least one person they have spoken with thanked them for the picture.

“Our son’s school’s headmaster is Scottish,” Malm said. “And he pulls me aside at pick up one day and he goes, ‘You know what, Perry? You’ve done more for Scottish tourism than anybody else in my lifetime.’

“So, hopefully some people will be inspired to come visit Scotland.”

What isn’t certain, however, is what they actually encountered on that cold April morning on the shore of Loch Ness.

“We don’t know what we saw,” Wiseman said. “Our children believe we saw Nessie, and I believe it for them.

“I believe that we saw something that could be Nessie, and that is a very broad possibility.”

Malm said the wonder that the sighting has inspired in his children, and others resonating with the photo, is more important than the question of what they encountered.

“It’s really charming,” he said of the outpouring of reactions. “Because in a world where the news is about a war here and an atrocity there, it’s just nice that people are interested in something that’s just lighthearted, a little bit silly and a little bit unbelievable.”

Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark nationalpost.com and sign up for our daily newsletter, Posted, here.

Article content

Comments

Join the Conversation

This Week in Flyers

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Media

B.C. online harms bill on hold after deal with social media firms

Published

 on

The British Columbia government is putting its proposed online harms legislation on hold after reaching an agreement with some of the largest social media platforms to increase safety online.

Premier David Eby says in a joint statement with representatives of the firms Meta, TikTok, X and Snapchat that they will form an online safety action table, where they’ll discuss “tangible steps” toward protecting people from online harms.

Eby added the proposed legislation remains, and the province will reactivate it into law if necessary.

“The agreement that we’ve struck with these companies is that we’re going to move quickly and effectively, and that we need meaningful results before the end of the term of this government, so that if it’s necessary for us to bring the bill back then we will,” Eby said Tuesday.

300x250x1

The province says the social media companies have agreed to work collaboratively with the province on preventing harm, while Meta will also commit to working with B.C.’s emergency management officials to help amplify official information during natural disasters and other events.

The announcement to put the Bill 12, also known as the Public Health Accountability and Cost Recovery Act, on hold is a sharp turn for the government, after Eby announced in March that social media companies were among the “wrongdoers” that would pay for health-related costs linked to their platforms.

At the time, Eby compared social media harms to those caused by tobacco and opioids, saying the legislation was similar to previous laws that allowed the province to sue companies selling those products.

A white man and woman weep at a podium, while a white man behind them holds a picture of a young boy.
Premier David Eby is pictured with Ryan Cleland and Nicola Smith, parents of Carson Cleland, during a news conference announcing Bill 12. (Ben Nelms/CBC)

Eby said one of the key drivers for legislation targeting online harm was the death of Carson Cleland, the 12-year-old Prince George, B.C., boy who died by suicide last October after falling victim to online sextortion.

“In the real world we would never allow a company to set up a space for kids where grown adults could be invited in to contact them, encourage them to share photographs and then threaten to distribute those photographs to their family and friends,” Eby said when announcing the legislation.

The premier said previously that companies would be shut down and their owners would face jail terms if their products were connected to harms to young people.

In announcing the pause, the province says that bringing social media companies to the table for discussion achieves the same purpose of protecting youth from online harm.

“Our commitment to every parent is that we will do everything we can to keep their families safe online and in our communities,” said Eby.

Ryan Cleland, Carson’s father, said in a statement on Tuesday that he “has faith” in Eby and the decision to suspend the legislation.

“I don’t think he is looking at it from a political standpoint as much as he is looking at it as a dad,” he said of Eby. “I think getting the social media giants together to come up with a solution is a step in the right direction.”

Business groups were opposed

On Monday, the opposition B.C. United called for a pause to Bill 12, citing potential “serious legal and economic consequences for local businesses.”

Opposition Leader Kevin Falcon said in a statement that his party pushed Eby’s government to change course, noting the legislation’s vague language on who the province can sue “would have had severe unintended consequences” for local businesses and the economy.

“The government’s latest retreat is not only a win for the business community but for every British Columbian who values fairness and clarity in the law,” Falcon said.

A white man wearing a blue tie speaks in a legislature building.
B.C. United Leader Kevin Falcon says that Bill 12 could have had unintended consequences. (Chad Hipolito/The Canadian Press)

The Greater Vancouver Board of Trade said they are pleased to see the legislation put on hold, given the “potential ramifications” of the proposal’s “expansive interpretation.”

“We hope that the government chooses not to pursue Bill 12 in the future,” said board president and CEO Bridgitte Anderson in a statement. “Instead, we would welcome the opportunity to work with the government to develop measures that are well-targeted and effective, ensuring they protect British Columbians without causing unintended consequences.”

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Trending